Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 29061729.
- Also identified by DOI 10.2337/db17-0802 and PMC identifier 5741144.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We examined the association between plasma 25-hydroxyvitamin D [25(OH)D] concentration and islet autoimmunity (IA) and whether vitamin D gene polymorphisms modify the effect of 25(OH)D on IA risk. We followed 8,676 children at increased genetic risk of type 1 diabetes at six sites in the U.S. and Europe. We defined IA as positivity for at least one autoantibody (GADA, IAA, or IA-2A) on two or more visits. We conducted a risk set sampled nested case-control study of 376 IA case subjects and up to 3 control subjects per case subject. 25(OH)D concentration was measured on all samples prior to, and including, the first IA positive visit. Nine polymorphisms in <i>VDR</i>, <i>CYP24A, CYP27B1, GC,</i> and <i>RXRA</i> were analyzed as effect modifiers of 25(OH)D. Adjusting for HLA-DR-DQ and ancestry, higher childhood 25(OH)D was associated with lower IA risk (odds ratio = 0.93 for a 5 nmol/L difference; 95% CI 0.89, 0.97). Moreover, this association was modified by <i>VDR</i> rs7975232 (interaction <i>P</i> = 0.0072), where increased childhood 25(OH)D was associated with a decreasing IA risk based upon number of minor alleles: 0 (1.00; 0.93, 1.07), 1 (0.92; 0.89, 0.96), and 2 (0.86; 0.80, 0.92). Vitamin D and <i>VDR</i> may have a combined role in IA development in children at increased genetic risk for type 1 diabetes.
Medical subject headings
- Autoimmunity
- Vitamin D